CAMBREX CORPORATION (NYSE:CBM) Files An 8-K Financial Statements and Exhibits
Item 9.01 – Exhibit

(c)Exhibit Index

Exhibit 3.1Amended and Restated By-Laws of Cambrex Corporation

CAMBREX CORP Exhibit
EX-3.1 2 ex_98790.htm EXHIBIT 3.1 ex_98790.htm Exhibit 3.1 (Marked to show changes)   AMENDED & RESTATED BY-LAWS OF CAMBREX CORPORATION   ARTICLE I – OFFICES   The registered office of Cambrex Corporation (the “Corporation”) in the State of Delaware shall be in the City of Wilmington,…
To view the full exhibit click here

About CAMBREX CORPORATION (NYSE:CBM)

Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities. The Company’s manufacturing facilities are located in the Europe and the United States. The Company’s business consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The Company’s products include active pharmaceutical ingredients (APIs), pharmaceutical intermediates and other fine chemicals. The Company’s products and services are sold around the world under trademarks that are owned by the Company. This includes Profarmaco, which is registered around the world as a word and design mark. Its products are sold through a combination of direct sales and independent agents.